Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 8;12:5377–5388. doi: 10.2147/OTT.S202026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Hu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Lycorine inhibits the JAK2/STAT3 signaling pathway by enhancing SHP-1 expression.

Notes: (A) MNNG/HOS and U2OS cells were treated with various concentrations of lycorine for 48 h and then the cell lysates were extracted for Western blot analysis by using antibodies specific to JAK2, p-JAK2, STAT3, p-STAT3, and SHP-1. (B, C) SHP-1 activity was measured in the cells 24 h after treatment with or without lycorine. (D) A schematic illustration of the hypothesized mechanism for the anti-OS activity of lycorine. Data are presented as the mean ± SD of three independent experiments. **P<0.001 vs control.

Abbreviations: JAK2, Janus kinase 2; STAT3, signal transducers and activators of transcription 3; SHP-1, SH2 domain-containing phosphatase 1.